J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chiu, C.-C.
Right arrow Articles by Lu, M.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chiu, C.-C.
Right arrow Articles by Lu, M.-L.

DRUG INTERACTIONS

Dose-Dependent Alternations in the Pharmacokinetics of Olanzapine During Coadministration of Fluvoxamine in Patients With Schizophrenia

Chih-Chiang Chiu, MD, Hsien-Yuan Lane, MD, PhD, Ming-Chyi Huang, MD, Hui-Ching Liu, MD, Michael W. Jann, PharmD, Yuen-Yi Hon, PharmD, Wen-Ho Chang, MD and Mong-Liang Lu, MD, MS

From the Laboratory of Biological Psychiatry, Taipei City Psychiatric Center, Taipei, Taiwan (Dr Chiu, Dr Huang); Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan (Dr Lane); Hung-Chi Psychiatric Hospital, Taipei, Taiwan (Dr Liu); Department of Clinical and Administrative Sciences, Southern School of Pharmacy, Mercer University, Atlanta, Georgia (Dr Jann); Clinical Pharmacokinetics Research Laboratory, Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, Maryland (Dr Hon); Department of Psychiatry, Dalin Tzu-Chi General Hospital and Tzu-Chi University, Hualien, Taiwan (Dr Chang); and Department of Psychiatry, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan (Dr Lu).

Olanzapine, an atypical antipsychotic agent, is a substrate of the cytochrome P4501A2 (CYP1A2) enzyme. Administration of a potent CYP1A2 inhibitor (eg, fluvoxamine) may alter the pharmacokinetics of olanzapine. This study investigated the pharmacokinetic interactions between olanzapine and fluvoxamine in patients with schizophrenia. Ten male smokers were administrated a single dose of olanzapine 10 mg at baseline, followed by 2 weeks of fluvoxamine 50 mg/day and another 2 weeks of fluvoxamine 100 mg/day. Olanzapine 10 mg was given at day 10 during each fluvoxamine treatment. After pretreatment with fluvoxamine, the area under the curve, maximal plasma concentration, and half-time of olanzapine were significantly increased by 30% to 55%, 12% to 64%, and 25% to 32%, respectively. Volume of distribution and apparent clearance were significantly reduced by 4% to 26% and 26% t O 38%, respectively, after administration of fluvoxamine. Increases in area under the plasma concentration-time curve from time 0 to infinity appear to be dose dependent. Presumably, altered olanzapine pharmacokinetics are attributed to the inhibition of CYP1A2. Patients treated with the combination of olanzapine and fluvoxamine should be monitored carefully.

Key Words: Olanzapine • fluvoxamine • drug interactions • schizophrenia

Address for reprints: Mong-Liang Lu, MD, Department of Psychiatry, Taipei Medical University-Wan Fang Hospital, No. 111, Hsin-Long Road, Sec. 3, Taipei, Taiwan.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Clinical Pharmacology